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Statement of Purpose: Polyhydroxyalkanoates or PHAs are a 
family of naturally occurring intracellular polymers 
synthesized by a variety of microorganisms. PHAs can be 
broadly classified into two types such as short chain length 
PHAs (scl-PHAs), containing 3-5 carbon atoms and medium 
chain length PHAs (mcl-PHAs) containing 6-14 carbon atoms 
within their monomer units. Their physical properties differ 
based on their type. Scl-PHAs, except for Poly(4-
hydroxybutyrate) are brittle, stiff and have a high melting 
point and glass transition temperature, whereas mcl-PHAs are 
soft, elastomeric and have low crystallinity, melting point and 
glass transition temperature. PHAs are known to be 
biocompatible and biodegradable in nature. They degrade into 
non-toxic byproducts via surface erosion thereby maintaining 
its bulk properties. They are currently being explored for 
several biomedical applications such as medical devices, 
tissue engineering and drug delivery systems1,2,3. In this study, 
a range of novel PHAs were produced, characterized and used 
for 3 different medical applications such as – (1) Development 
of coronary artery stents, (2) Nerve guidance conduits and (3) 
Cancer disease modelling.  
 
Methods:  Novel PHAs were produced via bacterial 
fermentation using Bacillus and Pseudomonas strains. They 
were extracted and purified using the soxhlet extraction. They 
were characterized using Gas Chromatography-Mass 
Spectrometry (GC-MS) and Nuclear Magnetic Resonance 
(NMR). Biocompatibility studies were carried out to ensure 
that the PHA produced were non-toxic in nature. Coronary 
artery stent prototypes were developed using the dip moulding 
process. Dip moulded PHA tubes were mechanically 
characterized and laser cut by means of a picosecond pulsed 
laseto achieve a specific design and strut dimensions. Nerve 
guidance conduits were developed using the micro extrusion 
process. Adhesion assay was carried out to investigate the 
biocompatibility of the PHA based nerve conduits. In vivo 
studies were carried out where PHA based nerve conduits 
were implanted in the rat model of sciatic nerve injury. 
Finally, PHA based 3D scaffolds were developed using the 
particulate leaching method. These porous scaffolds were used 
to understand the cellular behavior and mechanisms of breast 
cancer using the Breast cancer cell line MDA-MB 231. Cell 
viability and their morphology was assessed using Alamar 
blue assay, confocal microscopy and scanning electron 
microscopy.  
Results: A range of novel PHAs were produced as a result of 
extensive screening experiments. Based on their physical 
properties, purified PHAs were chosen for specific 
applications. Cell viability studies demonstrated that the PHAs 
produced were highly cytocompatible. For the development of 
coronary artery stents, PHA tubes were successfully produced 
using the optimised dip moulding and extrusion process. Their 
mechanical properties demonstrated significant post yield 
plastic deformation and elongation at break, while maintaining 
high stiffness and tensile strength. The tubes were 
successfully laser cut to achieve a specified design and strut 
dimensions. For the development of PHA based nerve 
guidance conduits, PHA tubes were successfully developed 
using the melt extrusion method. PHA based nerve conduits 
were cytocompatible and promoted neurite formation. In vivo 
studies demonstrated that, PHA based nerve guidance conduits 
promoted nerve regeneration in a rat model of sciatic nerve 
injury with a 10 mm gap. Finally, 3D scaffolds were 
successfully developed using a P(3HB)/mclPHA blend. The 
breast cancer cell line MDA MB 231 was used which 
demonstrated in vivo like clustered-rounded morphology when 
cultured on the 3D porous scaffolds.  
 
 
Figure1:  Development of PHA based coronary artery stent 
prototype, Nerve guidance conduits and cancer disease model. 
 
Conclusions:  A range of novel PHAs were produced and 
characterized. These biocompatible and biodegradable PHAs 
were successfully used in the development of coronary artery 
stent prototypes, nerve guidance conduits and a cancer disease 
model.  
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